This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ultragenyx (RARE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -62.40% and 33.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Ultragenyx (RARE) Down 22% Since Last Earnings Report?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA
by Zacks Equity Research
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.
Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -26.42% and 28.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA
by Zacks Equity Research
Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.
AbbVie (ABBV) Inks Deal to Acquire Medical Device Company
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.
Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance
by Zacks Equity Research
Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.
Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress
by Zacks Equity Research
Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.
The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics
5 Biotech Stocks That Have Gained More Than 200% in 2020
by Kinjel Shah
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate
by Zacks Equity Research
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Ultragenyx (RARE) Gets Orphan Drug Tag for Wilson Disease Drug
by Zacks Equity Research
Ultragenyx (RARE) gets Orphan Drug Designation from the FDA for UX701 for the treatment of Wilson disease.
Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?
by Zacks Equity Research
Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of 8.87% and 47.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Up 10.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of 47.44% and 53.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session
by Zacks Equity Research
Ultragenyx (RARE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.
Ultragenyx Gets FDA Nod for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval for the label expansion of Crysvita into tumor-induced osteomalacia.
Utragenyx Shares Soar Above 60% YTD on Pipeline Developments
by Zacks Equity Research
Ultragenyx's (RARE) shares rise more than 60% year to date on various positive pipeline developments.